Bölüm "Tıp Fakültesi, Dahili Tıp Bölümü" için listeleme
Toplam kayıt 21, listelenen: 21-21
-
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
(FUTURE MEDICINE LTD, 2023)Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative ...